theMednetRegister

Internal Medicine

Dermatology   

Questions discussed in this category

How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
The patient was diagnosed on the basis of ANA 1:1,280, strongly positive Smith, Sm-RNP, dsDNA, pericarditis, inflammatory arthritis, and discoid lupus...
2 Answers available
Would you be comfortable using isotretinoin in a female teenage patient who has a history of depression that is now stable but with a prior suicide attempt two years ago?
3 Answers available
What have you found to be effective for keratosis pilaris?
3 Answers available
Would you utilize rituximab or dupilumab for treatment resistant bullous pemphigoid?
4 Answers available
What therapies have you found most helpful for recalcitrant non-infectious cases of folliculitis?
3 Answers available
Have you seen CD30+ lymphoproliferative skin lesions with Upadacitinib treatment of atopic dermatitis?
1 Answer available
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics? 
3 Answers available
Do patient co-morbidities impact when you prescribe oral jak inhibitors?
Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?
3 Answers available
How would you treat disseminated flat warts in an immunosuppressed patient with skin of color?
How do you balance concern for causing skin hypopigmentation with many of the traditional treatment modalities we have?
2 Answers available
What is the maximum dose or treatment course of topical steroids that you generally recommend to avoid causing systemic adverse effects?
1 Answer available
Do you pursue a cardiac evaluation in all patients with an excised cutaneous myxoma?
1 Answer available
What is your approach to tapering treatments for patients with bullous pemphigoid?
2 Answers available
What is your treatment approach to prevent progression of phymatous rosacea?
Is isotretinoin the only effective option?
1 Answer available
Would you recommend continuing Accutane in a teenage female who has experienced a drop in calcium to 8.8 and reductions in albumin and protein levels one month into therapy?
Given that Accutane can affect calcium homeostasis, would you recommend continuing Accutane or are additional steps or workups warranted?
1 Answer available
What is your approach in counseling a patient with delusions of parasitosis?
4 Answers available
How would you approach treating patients with biopsy-proven Hailey-Hailey disease refractory to multiple oral therapies (i.e. tetracyclines, naltrexone, apremilast, glycopyrrolate, Cellcept), and requiring monthly steroid tapers for disease flares?
The disease is responsive to ablative lasers however laser treatments are not an option. 
5 Answers available
What is your treatment approach for hidradenitis suppurativa?
Do you reserve biologics for more systemic involvement? When do you initiate biologics such as secukinumab? 
1 Answer available
How do you approach managing nausea and GI side effects when initiating methotrexate?
3 Answers available
What therapies have you found most effective for managing patients with Darier disease?
2 Answers available
Are there any contraindications to starting a patient on Dupixent for prurigo nodularis if the patient is already on Xolair for asthma?
1 Answer available
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
2 Answers available
What alternative medications other than dapsone would you consider for dermatitis herpetiformis in a sulfa-allergic patient?
2 Answers available
How do you determine if a pyoderma gangrenosum lesion is “burned out"?
What changes do you make to your treatment approach to adapt to this altered disease state?
1 Answer available
What treatment approach is best for management of neutrophilic dermatosis in a patient with acute myeloid leukemia? Any suggestions for long term management?
1 Answer available
After corticosteroids, what second line agent do you select to treat drug induced hypersensitivity syndrome (also known as DRESS syndrome)?
1 Answer available
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?
1 Answer available
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...
3 Answers available
What are the benefits and potential risks of using bisphosphonates for pseudoxanthoma elasticum?
2 Answers available
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
Would you view this as a sign that disease is not adequately controlled despite labs and imaging suggesting no active vasculitis? 
1 Answer available
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
1 Answer available
What treatments have you found most effective in removing syringomas?
What specific settings and devices do you prefer to use? 
3 Answers available
What treatment modalities have you had success with for treating recalcitrant warts?
5 Answers available
How do you approach Pityriasis rubra pilaris that is retinoid resistant?
Do you have a preference for biologics or phosphodiesterase inhibitors? 
3 Answers available
Are you comfortable utilizing Stelara (ustekinumab) as biologic treatment of psoriasis for patients with a history of severe latex allergy?
1 Answer available
What role does oral roflumilast play in dermatology?
1 Answer available
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
3 Answers available
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.
1 Answer available
How do you manage polymorphic light eruption (PMLE)?
3 Answers available
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
Would you be comfortable combining a TNFi with Rituxan in this patient? 
1 Answer available
What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?
1 Answer available
What is your approach for severe SCLE in patients unable to tolerate HCQ?
3 Answers available
Do you utilize AIT for atopic dermatitis if there is no AR present?
4 Answers available
What therapies do you recommend for patients with recalcitrant seborrheic dermatitis?
What treatment regimen have you found most effective? Do you recommend any lifestyle changes or prescribe oral azoles? Any experience with topical r...
2 Answers available
How do you reassure families that no allergy testing is needed for urticaria?
2 Answers available
What work up do you pursue for splinter hemorrhages in an otherwise healthy patient?
1 Answer available
How do you approach treating patients who develop psoriasis while on Dupixent?
Do you start/trial them on another biologic or just rely on topical therapies?
1 Answer available
How have you incorporated biologics targeting the IL-36 pathway (e.g. Spevigo) into your treatment algorithm for psoriasis?
1 Answer available
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
1 Answer available
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
2 Answers available
What is your experience managing patients with chronic spontaneous urticaria occurring only at night?
Female in her early 40s with chronic spontaneous urticaria occurring consistently only at night for the past 4 years. Lesions develop only at night wh...
1 Answer available
What is your stepwise approach to a patient with erosive gingivitis?
 What treatment do you initiate before you have a clear diagnosis?
1 Answer available
In difficult cases, what is your approach to find a causative agent of fixed drug or fixed food eruption?
Drug elimination is often helpful, but some triggers are not easy to identify because they are found in food items.
1 Answer available
Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?
1 Answer available
What is your approach to management of radiation-induced bullous pemphigoid?
1 Answer available
How do you approach managing perioperative anxiety in Mohs patients?
1 Answer available
What is your approach to managing pyoderma gangrenosum recalcitrant to oral steroids?
When do you switch to steroid-sparing medications? What steroid-sparing therapies do you prefer?
7 Answers available
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
2 Answers available
Is there a role for empiric scabies treatment in itchy patients without clear clinical signs of scabies? 
Do you empirically treat itchy patients -with a non specific rash- for scabies without obvious clinical findings for scabies? 
5 Answers available
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
1 Answer available
What topical therapies have you found most effective for managing scalp psoriasis?
Do you use combination therapies such as betamethasone and calcipotriene foam?
1 Answer available
Do you wait on initiating biologic therapy for guttate psoriasis?
If so, how long? 
1 Answer available
What biologic for psoriasis do you prescribe most often in patients with a history of malignancy?
4 Answers available
How do you dose oral tranexamic acid for melasma?
Given the side effect profile and risk of relapse off oral TXA therapy, do you prefer pulse dosing (i.e. 3 months on, 3 months off) or continuous ther...
1 Answer available
How do you approach work up for underlying rheumatologic disease in patients referred for chronic urticaria?
2 Answers available
How do you approach treatment change in patients with psoriasis who have been stable on an IL-17 or IL-23 agent but then begin to have breakthrough skin disease?
Do you first try adding topicals or UV? At what point do you decide to switch biologics and at that point do you try to class switch to a different MO...
2 Answers available
How are you utilizing vibratory devices for reducing pain associated with injection or procedures?
In which situations or patient populations do you find this useful? How is it sterilized?
3 Answers available
What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?
1 Answer available
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?
2 Answers available
How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?
Are there patients that you find respond best to these therapies?
3 Answers available
Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?
2 Answers available
How does the location or type of psoriasis affect your initial biologic choice?
1 Answer available
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
4 Answers available
How would you treat pemphigus foliaceous in an elderly patient intolerant to oral steroids?
2 Answers available
What are the best biologics for a pediatric patient with extensive guttate psoriasis that is poorly controlled on topicals?
Mother's insurance plan has a high deductible and phototherapy is inconvenient (family lives 50 minutes away). 
2 Answers available
What are some practical tips for caring for resource-limited patients with severe, Hurley Stage III hidradenitis suppurativa?
For instance - any tips regarding coordination of care/transportation, associated lymphedema management, wound care, and pain control would be welcome...
1 Answer available
For how long would you treat Klebsiella aerogenes folliculitis of the face manifesting as a cystic lesion?
Would you combine antibiotics with isotretinoin?
2 Answers available
How frequently do you recommend skin cancer screens in your patients with kidney transplants who are on immunosuppression?
3 Answers available
Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?
2 Answers available
How do you approach patients that develop atopic dermatitis while on biologics for psoriasis?
I have an elderly patient with a history of biopsy-proven psoriasis on IL-17 biologic therapy. She has developed an intense itch without a primary ras...
1 Answer available
What lifestyle modifications do you recommend for patients with hidradenitis suppurativa?
3 Answers available
What treatment modalities have you had success with for treating extensive molluscum in the pediatric population?
1 Answer available
What lab monitoring and frequency do you recommend in an otherwise healthy young patient on biologics for psoriasis?
With no high-risk exposure do you repeat quant gold?
4 Answers available
How do you approach treating disseminated granuloma annulare?
Do you order blood work to evaluate for underlying dyslipidemia or other metabolic diseases?
6 Answers available
How do you manage axillary hyperhidrosis that is refractory to oral glycopyrrolate and aluminum-based antiperspirants in patients with neuromuscular disorders?
6 Answers available
How do you manage atopic dermatitis in pediatric patients who has failed dupilumab?
(preschool-aged patients)
1 Answer available
How do you approach HS patients with persistent HS lesions on the trunk?
Have you had success with deroofing or surgical excision? Is ILK the best option?
2 Answers available
What is your treatment algorithm for managing porokeratosis?
2 Answers available
How would you work up a patient with cutaneous mastocytosis?
Is a BM biopsy a must when there is skin involvement? If tryptase level is mildly elevated but less than 20 would you recommend a BM biopsy?
1 Answer available
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
1 Answer available
What nutritional supplements do you recommend for patients with hair loss?
Have you recommended supplementing less common supplements such as zinc or selenium?
2 Answers available
What exfoliative regimen do you recommend for patients with recurrent plantar keratoderma?
1 Answer available
What scented alternatives do you recommend patients with fragrance allergies try to replace perfumes/colognes?
Do your recommendations differ depending on the fragrance category (i.e fragrance mix I, II or balsam of Peru)?
3 Answers available
What biologics have you found to be most effective in treating hidradenitis suppurativa?
How do you navigate insurance coverage?
1 Answer available
Do you recommend testing for HPV in patients with oral lichen planus?
2 Answers available
What skin care regimen do you prefer during radiation for patients with inflammatory breast cancer?
Are there any skin care products you would avoid in this population?
5 Answers available
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
1 Answer available
Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?
How has this impacted your counseling and management?
2 Answers available
Any concern for lupus flare in patients undergoing laser hair removal?
2 Answers available
Do you transition to a topical retinoid after a patient completes a course of isotretinoin?
And if so how soon after do you start?
6 Answers available
What recommendations do you make for patients with lower abdomen eczema from nickel in their belt buckle?
1 Answer available
What is your preferred workup for a patient who has a biopsy consistent with “dermal hypersensitivity reaction”?
What treatment modalities have you tried for "dermal hypersensitivity reaction"? 
3 Answers available
What is your approach to patients with SLE who develop a rash after hydroxychloroquine initiation?
3 Answers available
What is your approach for disease activity monitoring in patients with sarcoidosis?
1 Answer available
What’s your approach to recurrent “idiopathic” Erythema Nodosum that failed NSAIDs?
What’s your preferred NSAIDs and next steps?
1 Answer available
Do you have to remove gold dental crowns if patch testing reveals a gold allergy?
1 Answer available
Do you prescribe fluocinolone in peanut oil in patients with peanut allergies?
3 Answers available
What is your approach to treating genital lichen sclerosus that is not responding to super-potent topical steroids?
1 Answer available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).
2 Answers available
How do you perform patch testing in patients who are allergic to adhesives?
1 Answer available
Does IVIG or subcutaneous Ig interfere with monoclonal antibody therapy (i.e. dupilumab, infliximab, rituximab, etc)?
How should IVIG and either biologic injections or infusions be spaced?
2 Answers available
How do you manage recurrent urticarial lesions in a patient with underlying connective tissue disease that is otherwise well-controlled?
3 Answers available
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
4 Answers available
How do you approach treating patients with delusions of parasitosis who can not tolerate an antipsychotic?
1 Answer available
What therapies have you found most effective for treating lower extremity DSAP?
Have you had success with topical lovastatin or PDT?
1 Answer available
What is your approach to severe discoid lupus refractory to conventional topical and systemic therapies?
(Refractory to mycophenolate, azathioprine, and methotrexate. UpToDate suggests thalidomide or IVIG with mixed efficacy, while there are some case rep...
5 Answers available
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
1 Answer available
What is your approach to evaluation in patients who present with erythromelalgia?
1 Answer available
Does Dupixent interfere with patch testing?
https://www.jaad.org/action/showPdf?pii=S0190-9622%2824%2903329-2
1 Answer available
Have you seen drug induced SCLE from IL-17 inhibitors?
And if so, what is your approach to the diagnosis?
1 Answer available
What treatments do you recommend and how do you counsel patients with postpartum hair loss?
Do you recommend any dietary changes or supplements? Do you modify your recommendations if the patient is breast feeding?
2 Answers available
How will you utilize newly FDA approved anifrolumab for SLE in your practice?
2 Answers available
What initial workup do you perform when there is a concern for porphyria?
1 Answer available
How do you counsel patients who report a history of a lidocaine allergy?
1 Answer available
What treatments and resources have you found helpful for ichthyosis vulgaris patients?
3 Answers available
What treatments would you recommend for patients with chronic urticaria who have minimal improvement with anticholinergics and Xolair?
Have you tried any of the newer biologics?
3 Answers available
How do you manage pityriasis lichenoides chronica (PLC)?
Do you typically order a systemic workup? And, after topical corticosteroids, what other treatment options do you prefer?
1 Answer available
How do you monitor patients with cutaneous lupus for progression to SLE?
Do you do blood work? Or do you rely on review of systems?
1 Answer available
How do you counsel parents of children with atopic dermatitis about preventing recurrent Staph infections?
Are dilute bleach baths enough? Should they use any topical therapies? Is there a need for Staph decolonization with something like mupirocin?
1 Answer available
How do you approach treating patients with lupus profundus?
Do you typically start the patient on hydroxychloroquine?  What work-up do you perform?
1 Answer available
How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?
In what cases do you discontinue the medication?
2 Answers available
How do you approach the diagnosis of erythronychia?
1 Answer available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
What is your approach to the use of intravenous sodium thiosulfate for the management of calciphylaxis in a patient with end stage kidney disease and on hemodialysis?
1 Answer available
Do you use apremilast in combination with biologic DMARDs for psoriatic arthritis and/or psoriasis?
Are there ways to overcome barriers in insurance coverage of this combination of treatments?
2 Answers available
At what age do you recommend annual skin exams in a patient without a personal or family history of skin cancer?
Any evidence behind this practice?
2 Answers available
What prescription or over-the-counter therapies have you found effective for helping vitiligo patients cover active areas?
3 Answers available
How do you approach treating nail lichen planus?
2 Answers available
What topical therapies do you most commonly prescribe for rashes near the eyes?
1 Answer available
What is your treatment algorithm for patients with lichen planus?
2 Answers available
Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?
Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...
1 Answer available
Do all patients initiating omalizumab need to have it administered in a healthcare setting?
1 Answer available
What therapies have you found most effective in providing rapid improvement in patients with erythrodermic atopic dermatitis?
1 Answer available
What treatments have you found helpful in treating recurrent aphthous ulcers?
2 Answers available
What lab monitoring do you perform for patients taking isotretinoin?
What labs do you order? How often do you order labs?  Have you ever needed to discontinue isotretinoin due to lab abnormalities?
2 Answers available
How do you manage patients with hand dermatitis recalcitrant to potent topical steroids?
4 Answers available
When do you refer pediatric patients with eczema to an allergist?
Are there cases where food or environmental allergies significantly worsen eczema in children?
1 Answer available
What is your treatment approach to persistent chillblains lesions in the absence of systemic lupus?
1 Answer available
What treatments have you found to be most effective in treating oral lichen planus?
Does your treatment management differs for oral erosive lichen planus? How would you approach patients with active malignancy on chemo and radiation?
4 Answers available
Do you routinely check G6PD level prior to initiation of hydroxychloroquine?
6 Answers available
Have you had success using resorcinol 15% topically for limited hidradenitis?
If so, where can patients find it? And besides topical clindamycin, what other topicals do you find helpful for individual lesions?
2 Answers available
How do you manage polymorphous eruption of pregnancy (formerly PUPPP)?
The symptoms can be really miserable.I try to control it with antihistamines (don't find these helpful in most cases) and topical steroids, but that d...
1 Answer available
Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?
2 Answers available
What topical therapies do you find are most effective for treating inverse psoriasis in areas of the body with thinner skin?
4 Answers available
What methods do you use to prophylactically reduce radiation dermatitis for head and neck irradiation?
4 Answers available
What recommendations do you provide to patients who develop ocular side effects with Dupixent?
Do you refer them to Ophthalmology? Have you had to switch patients off of Dupixent due to their ocular side effects?
3 Answers available
Do you routinely provide GI protection in the form of a PPI or histamine blocker for patients with immunobullous disease initiated on high doses of oral corticosteroids?
1 Answer available
How do you approach the management of patients on lamotrigine who develop a minor rash?
Should one restart lamotrigine or look for an alternative? If no other alternative available, is slow titration vs regular titration preferred?
4 Answers available
How do you determine if a positive thimerosal patch test isn't a false positive?
Is a positive thimerosal test always a false positive?
1 Answer available
Do you recheck screening labs (ESR, BUN/Cr, urinalysis, ANA, etc) for patients with recurrent small vessel vasculitis of unknown origin with each flare?
1 Answer available
How do you manage patients on biologics peri-operatively?
Are there any medications that surgeons like discontinued before their procedure?
1 Answer available
What is your approach to ongoing assessment and medication tapering in well controlled discoid lupus without systemic features?
3 Answers available
What topical therapies and procedures do you recommend for patients with atrophic acne scarring?
1 Answer available
What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?
1 Answer available
Do you hold histone deacetylase (HDAC) inhibitors for patients receiving palliative radiation therapy for cutaneous lymphomas?
If so, how long before/after radiation?
1 Answer available
What topical or oral treatments do you recommend for patients with recurrent MRSA infections?
Do you recommend any changes to their personal hygiene practices? or changes to their environment?
1 Answer available
What dressings do you recommend for patients with hidradenitis suppurativa to help prevent friction and collect drainage from open areas?
Especially after surgical procedures
2 Answers available
What is your treatment approach for steroid-refractory necrobiosis lipoidica?
Any success with hydroxychloroquine?
1 Answer available
How do you approach treating patients with erythema nodosum recalcitrant to NSAIDs?
1 Answer available
What maintenance therapies do you most commonly recommend for patients with improving genital lichen sclerosis?
What recommendations do you provide if there is concern that the patient is beginning to flare? Have you prescribed any of the new JAK inhibitors?
2 Answers available
How do you approach treating patients with trigeminal trophic syndrome?
2 Answers available
How do you approach the treatment of bullous cutaneous lupus?
When would you de-escalate therapy?
1 Answer available
How would you treat localized cutaneous PAN recalcitrant to high-dose steroids?
1 Answer available
Where do oral and topical JAK inhibitors fit into your treatment algorithm and approach to atopic dermatitis?
2 Answers available
What is your approach to a young adult patient with significant nail psoriasis and not much cutaneous disease?
1 Answer available
What are some of your preferred treatment options for managing facial papules that occur in the setting of lichen planopilaris?
1 Answer available
What is your approach to starting and monitoring methotrexate in elderly patients?
1 Answer available
How do you evaluate livedo reticularis (not livideo racemosa)?
Does your evaluation hinge on nonresolution with warming? How extensive is your workup?
1 Answer available
What is your work-up for acquired keratoderma?
Does morphology guide your workup?
1 Answer available
When do you prescribe clascoterone cream for your acne patients?
In your experience, do specific patient features predict a better response?
1 Answer available
What is your experience with iontophoresis for hyperhidrosis?
1 Answer available
How do you approach treating necrobiosis lipoidica, especially cases that have ulcerated?
1 Answer available
With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?
Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?
2 Answers available
If you have clinical suspicion for a paraneoplastic process (e.g. dermatomyositis or pemphigus), what work-up do you pursue?
1 Answer available
What treatment regimen do you start for patients who present with mucous membrane pemphigoid?
 Have you prescribed Rituximab and IVIG simultaneously for patients?
1 Answer available
How do you manage patients with erosive pustular dermatosis?
1 Answer available
What are your preferred treatment options for patients with chronic non-healing leg ulcers?
1 Answer available
What therapies do you recommend for preventing keloid recurrence after surgical resection?
1 Answer available
How do you manage patients with Dercum's disease?
2 Answers available
What is your approach to treating patients with dupilumab induced facial redness?
2 Answers available
Do you recommend the HPV vaccine for patients with recalcitrant verruca vulgaris?
2 Answers available
How do you manage patients with chronic flushing that do not respond to beta-blockers?
1 Answer available
How do you manage patients with bullous pemphigoid who have IgE autoantibodies to BP180?
1 Answer available
How do you manage patients with rapidly progressing vitiligo?
1 Answer available
How do you manage patients with cicatricial pemphigoid refractory to doxycycline and dapsone?
1 Answer available
How do you manage patients with chemotherapy-induced paronychia?
1 Answer available
How do you approach treating cutaneous PAN?
Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease? 
1 Answer available
How would you manage a patient with essential thrombocythemia and persistent pruritus despite adequate control of CBC with hydroxyurea and aspirin?
ET is JAK2+
1 Answer available
How do you manage psoriasis in pregnant patients?
3 Answers available
How do you approach restarting biologics for psoriasis patients who have discontinued therapy for 3-6 months?
Do you prefer restarting the biologic with the loading or maintenance dosing?
1 Answer available
How do you approach patients with onychomycosis that does not respond to terbinafine and prolonged courses of fluconazole?
Would you switch to itraconazole or perform fungal cultures? When would you consider repeating the course of treatment? 
2 Answers available
How do you differentiate atopic dermatitis from mycosis fungoides histologically?
1 Answer available
How do you manage patients with suspected chronic contact dermatitis and negative patch testing?
1 Answer available
How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?
Do you have a preferred sequence of therapies for diffuse skin limited MF?
1 Answer available
Have you found success in managing refractory hidradenitis suppurativa with ertapenem?
1 Answer available
Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?
1 Answer available
What is your preferred infliximab dosing strategy for hidradenitis suppurativa?
2 Answers available
How do you approach the use of commercial testing such as AVISE CTD in clinical practice?
1 Answer available
How do you clinically distinguish between cutaneous lupus with photosensitivity and polymorphic light eruption-like reactions?
1 Answer available
What is the role for angiography in the workup of digital ischemia?
Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?
1 Answer available
Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?
In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect? 
1 Answer available
What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?
1 Answer available
How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?
Would you change rituximab maintenance dose or schedule?
1 Answer available
How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?
1 Answer available
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
ADVOCATE trial
1 Answer available
When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?
2 Answers available
How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
1 Answer available
Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...
1 Answer available
Is it okay to use medications associated with drug-induced lupus in patients with SLE?
1 Answer available
How would you approach refractory gangrenous Raynaud's secondary to type one cryoglobulins?
What if the patient has MGUS? Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?
1 Answer available
Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?
1 Answer available
Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?
1 Answer available
Is there a role for measuring hydroxychloroquine blood levels in clinical practice?
If so, are there specific patient populations for which you would use this metric?
1 Answer available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?
5 Answers available
Should venous thrombosis in a patient with Behcet syndrome be treated with both immunosuppression and anticoagulation?
1 Answer available
How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?
1 Answer available
Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?
2 Answers available
Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?
1 Answer available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
How do you assess transaminitis in a patient with sarcoidosis with known liver involvement being treated with methotrexate?
1 Answer available
Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?
1 Answer available
When is a biopsy necessary to diagnose relapsing polychondritis?
1 Answer available
What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?
1 Answer available
How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?
1 Answer available
What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?
1 Answer available
Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
 If you use both, how do you decide which to use for a particular patient?
2 Answers available
Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?
1 Answer available
How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?
This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet
1 Answer available
Is there a minimum work-up necessary in patients with an ANA greater than 1:160 and no clinical symptoms suggestive of lupus (i.e., specific antibodies, UA)?
2 Answers available
Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?
1 Answer available


Papers discussed in this category

N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Medicine (Baltimore),
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
J. Am. Coll. Cardiol.,
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Arthritis and rheumatism, 1982-11
The 1982 revised criteria for the classification of systemic lupus erythematosus.
Arthritis and rheumatism, 2012-08
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
, 2019 Aug 06
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Arthritis Rheum.,
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Ann. Rheum. Dis., 2017 May 25
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Medicine, 1976-05
Relapsing polychondritis: prospective study of 23 patients and a review of the literature.
Arthritis and rheumatism, 2010-01
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
J. Rheumatol., 2019 Sep 01
Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.
Annals of the rheumatic diseases, 2009-03
EULAR recommendations for the management of primary small and medium vessel vasculitis.
JAMA ophthalmology, 2014-12
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Can J Ophthalmol,
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
J Am Acad Dermatol, 2016 Feb 03
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008-10
Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Clin Rheumatol, 2006 Dec 21
Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.
Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Kidney international reports, 2018-03
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
Rheumatology (Oxford),
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Journal of psoriasis and psoriatic arthritis, 2019-04
TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Front Pharmacol, 2019 Mar 26
Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.
Nat Rev Dis Primers, 2018 Aug 02
Cryoglobulinaemia.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Int J Clin Pract, 2021 Mar 24
Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
Mod Rheumatol, 2021 Feb 09
QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Heart Rhythm, 2020 Jun 28
Effects of hydroxychloroquine treatment on QT interval.
Arthritis care & research, 2018-03
Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.
J Clin Rheumatol, 2020 Sep 18
Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.
Cureus, 2020 Aug 02
A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.
Ann Intern Med,
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Rheum Dis, 2011 Nov 29
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Respir Med, 2012 Apr 09
The treatment of pulmonary sarcoidosis.
Am J Respir Crit Care Med,
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
Autoimmunity reviews, 2009-02
The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.
Arthritis and rheumatism, 2013-07
Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.
Arthritis Rheumatol, 2021 Mar 24
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
Rev Med Interne, 2016 Oct 13
[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].
Arthritis Care Res (Hoboken), 2021 Mar 30
Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
JAMA Dermatol,
Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Mod Rheumatol, 2020 Sep 17
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
Ann Rheum Dis, 2014 Feb 13
The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Ann Rheum Dis, 2019 Jan 04
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
Ann Rheum Dis, 2014 Apr 16
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
N Engl J Med, 2019 Dec 18
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Seminars in arthritis and rheumatism, 2010-12
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Clin Exp Rheumatol, 2012 Oct 17
Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Inflamm Bowel Dis,
Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Am J Clin Dermatol,
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2001
Polyarteritis nodosa: spectrum of angiographic findings.
International journal of clinical rheumatology, 2010
Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.
Lupus science & medicine, 2014
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.
The Journal of rheumatology, 2015-11
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Ophthalmology, 2016-06
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Lupus science & medicine, 2017
Cell-bound complement activation products in SLE.
Journal of immunology research, 2017
Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.
Lupus science & medicine, 2018
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
Arthritis care & research, 2019-07
Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.
Clin Pharmacol Ther, 2018 Jun
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.
Lupus Sci Med, 2016
Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
Lupus Sci Med, 2016 Feb 01
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Lupus Sci Med,
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
ACR Open Rheumatol, 2020 Oct 12
Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).
Arthritis Rheumatol, 2021 May 02
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Ann Rheum Dis, 2012 Nov 10
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Arthritis Rheum,
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis Rheumatol, 2020 Jan 07
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Lupus Sci Med, 2019
Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.
Int J Dermatol,
Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease.
J Am Acad Dermatol,
Oral dexamethasone pulse treatment for vitiligo.
Br J Dermatol, 2018 Oct 10
Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo.
J Am Acad Dermatol, 2019 Mar 11
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.
J Am Acad Dermatol, 2019 May 13
Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.
Dermatology,
Infliximab for the treatment of hidradenitis suppurativa.
Best practice & research. Clinical rheumatology, 2013-06
Cutaneous lupus erythematosus: diagnosis and treatment.
Dermatol Ther, 2016 Apr 12
Review of treatment for discoid lupus erythematosus.
JAMA Dermatol,
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
J Dermatol,
Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases.
J Am Acad Dermatol, 2021 Jul 02
Efficacy and safety of treatments in cutaneous polyarteritis nodosa: A French observational retrospective study.
Ann Plast Surg,
Optimizing Radiotherapy for Keloids: A Meta-Analysis Systematic Review Comparing Recurrence Rates Between Different Radiation Modalities.
Journal of psychiatric practice, 2018-11
Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use.
Journal of the American Academy of Dermatology, 2019-05
Diagnosis and management of delusional parasitosis.
Med Hypotheses, 2006 Nov 28
Delusional parasitosis and the dopamine transporter. A new insight of etiology?
J Am Acad Dermatol, 2021 Apr 18
Stimulant use in patients presenting with psychocutaneous disorders.
Prog Neuropsychopharmacol Biol Psychiatry,
Effects of pimozide on the psychopathology of delusional disorder.
Antimicrob Agents Chemother, 2008 Nov 17
A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of Listeria monocytogenes infection.
Rheum Dis Clin North Am, 2020 Aug
Risk Factors and Cancer Screening in Myositis.
Rheumatology (Oxford),
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.
Am J Clin Dermatol,
Acquired palmoplantar keratoderma.
JAMA Dermatol, 2022 Mar 01
Treatment of Familial Benign Chronic Pemphigus With Superficial Radiotherapy.
Am J Clin Dermatol,
Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment.
J. Clin. Oncol., 2004-04-15
Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer.
Int J Radiat Oncol Biol Phys,
Measurement of 6-MV X-ray surface dose when topical agents are applied prior to external beam irradiation.
Eur J Dermatol,
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series.
Arthritis Res Ther, 2021 Sep 04
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
Journal of the American Academy of Dermatology, 2011-05
Quality of life in cutaneous lupus erythematosus.
Lupus, 2016 May 27
Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.
Clin Exp Rheumatol, 2013 Aug 02
Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity.
J Rheumatol, 2022 Aug 01
Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities.
Dermatol Ther, 2014 Aug 12
Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial.
Medicine (Baltimore), 2019 Dec
Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas.
J Clin Invest, 2013 Nov 15
Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice.
Clinical pharmacokinetics, 2018-12
Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
Frontiers in immunology, 2018
Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.
Clinical immunology (Orlando, Fla.), 2020 Jul 15
The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease.
The Pediatric infectious disease journal, 2018 Oct
Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017 Nov 03
Successful IVIG treatment without discontinuation of TNF-α blocker in Guillain-Barre syndrome induced by adalimumab in patient with Crohn's disease.
The Journal of rheumatology, 2012-01
Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
JAAD Case Rep, 2019 Oct 10
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.
Arthritis Care Res (Hoboken), 2022 Aug 04
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
JAMA dermatology, 2018-10-01
Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
,
Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.
Archives of dermatology, 2002 Sep
Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
JAMA dermatology, 2018-12-01
Effectiveness of the Tacrolimus Swish-and-Spit Treatment Regimen in Patients With Geographic Tongue.
J Cutan Aesthet Surg, 2019 Apr-Jun
Management of Rhinophyma with Radio Frequency: Case Series of Three Patients.
JAMA Dermatol, 2022 Aug 01
Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study.
Proceedings of the National Academy of Sciences of the United States of America, 2010 Apr 19
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.
Dermatol Ther, 2021 May
Successful systemic treatment outcomes of lichen planus: A single-center retrospective review.
Current rheumatology reviews, 2019
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Am J Clin Dermatol, 2022 Jun 23
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.
Ann Afr Med, 2020 Jul-Sep
Refractory lupus panniculitis treated successfully with rituximab: Two cases.
Arch Dermatol, 2006 Mar
Lupus erythematosus profundus successfully treated with dapsone: review of the literature.
Clin Rev Allergy Immunol, 2010 Apr
Intravenous immunoglobulin in lupus panniculitis.
Lupus, 2020 Mar 19
Successful treatment of refractory lupus erythematosus profundus with the interleukin-6 antagonist tocilizumab: a case report.
N Engl J Med, 2022 Oct 06
Trial of Intravenous Immune Globulin in Dermatomyositis.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023 Feb 11
Eczematized psoriasis - a frequent but often neglected variant of plaque psoriasis.
Clinical rheumatology, 1988 Sep
Treatment of psoriatic arthritis with sulphasalazine: a one year open study.
Journal of the American Academy of Dermatology, 1987 Apr
Gold therapy and its indications in dermatology. A review.
Journal of the American Academy of Dermatology, 2020 May 19
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
JAAD case reports, 2020 Aug 20
Successful treatment of refractory folliculitis decalvans with apremilast.
Science advances, 2024 Jul 03
Targeting IL-1 controls refractory pityriasis rubra pilaris.
Annals of the rheumatic diseases, 2023 May 29
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Clinical and experimental dermatology, 2021 Mar 09
Brodalumab-induced subacute cutaneous lupus erythematosus.
JAAD case reports, 2019 Mar 01
Ustekinumab-induced subacute cutaneous lupus.
Dermatologic therapy, 2020 May 03
Secukinumab-induced subacute cutaneous lupus erythematosus.
The Journal of allergy and clinical immunology, 2012 Feb 14
Chronic urticaria and autoimmunity: associations found in a large population study.
Lupus, 2019-05
Photosensitivity and photoprotection in patients with lupus erythematosus.
Journal of the American Academy of Dermatology, 2020 Apr 28
Cosmetic treatment in patients with autoimmune connective tissue diseases: Best practices for patients with lupus erythematosus.
The British journal of dermatology, 2003 Jul
Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol.
Journal of the American Academy of Dermatology, 2020-01
Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.
Journal of the American Academy of Dermatology, 2020 Apr 26
Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: A retrospective analysis of 58 patients.
Journal of drugs in dermatology : JDD, 2023 Oct 01
Cidofovir in the Management of Non-Genital Warts: A Review.
Journal of the American Academy of Dermatology, 2003-04
Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive.
Annals of the rheumatic diseases, 2018-09
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Arthritis & rheumatology (Hoboken, N.J.), 2019-02
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
RMD open, 2020 Feb
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Trials, 2022 Sep 05
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 24
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).
Annals of the rheumatic diseases, 2024 Mar 18
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Ann Rheum Dis, 2020 Dec 17
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Journal of the American Academy of Dermatology, 2023 Dec 07
Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study.
JAMA dermatology, 2020 May 01
Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy.
Photodermatology, photoimmunology & photomedicine, 2023 Dec 07
Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.
Clinical and experimental dermatology, 2024 Apr 23
Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study.
Allergy, 2021 Oct 20
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
Allergy, asthma & immunology research, 2020 Sep
Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea.
The journal of allergy and clinical immunology. In practice, 2018 Jul-Aug
How to Approach Chronic Inducible Urticaria.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2009 Nov 23
Recommendations for performing and evaluating the results of the minor test according to a sweating intensity visual scale.
American journal of clinical dermatology, 2022 Sep 15
Cholinergic Urticaria: Subtype Classification and Clinical Approach.
The Journal of allergy and clinical immunology, 2022 Sep 30
Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023 Dec 18
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.
Transplant international : official journal of the European Society for Organ Transplantation, 2019 Oct 07
Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study.
The British journal of dermatology, 2020 Apr 13
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Arthritis care & research, 2016 Jan
Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lupus, 2014 Feb 06
Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity.
Annals of the rheumatic diseases, 2023 Oct 12
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Journal of the American Academy of Dermatology, 2015 Jan 30
Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
Journal of the European Academy of Dermatology and Venereology : JEADV, 2016 Dec 20
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
American journal of clinical dermatology, 2020 Aug
Dermatologic Sequelae Associated with Radiation Therapy.
Arthritis care & research, 2023 Nov 28
Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995-02
Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema.
The journal of allergy and clinical immunology. In practice, 2021 Mar
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
The journal of allergy and clinical immunology. In practice, 2021 Apr 20
The Diagnostic Workup in Chronic Spontaneous Urticaria-What to Test and Why.
The journal of allergy and clinical immunology. In practice, 2020 Mar 13
Delayed Pressure Urticaria: A Systematic Review of Treatment Options.
The journal of allergy and clinical immunology. In practice, 2024 Feb
Skin Testing in Fixed Drug Eruptions: A Useful and Safe Tool?
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Autoimmunity reviews, 2023 Dec 20
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Antibiotics (Basel, Switzerland), 2023 May 29
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.
Clinical kidney journal, 2016 Nov 10
Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.
Expert review of anticancer therapy, 2009-01
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Lancet Gastroenterol Hepatol, 2023 Feb 01
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Related Topics in Internal Medicine

Copyright © 2024 theMednet
All Rights Reserved.